Protease susceptibility II
View Patent ↗The present invention relates to: manipulation of the amino acid sequence of tropoelastin, particularly human tropoelastin, to modify its protease susceptibility; to tropoelastin derivatives having modified protease susceptibility; to peptidomimetic molecules which contain amino acid sequences which correspond to or incorporate the protease susceptible sequences of tropoelastin; and to uses of the tropoelastin derivatives and peptidomimetic molecules. The invention also relates to nucleic acid molecules and genetic constructs encoding the amino acid sequences of the derivatives and peptidomimetic molecules of the invention.
1. A method of reducing the susceptibility of tropoelastin to proteolysis by thrombin, kallikrein or serum, comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 106 (RAAAG) in the tropoelastin, so that susceptibility of the tropoelastin to cleavage by thrombin, kallikrein or serum is reduced.
2. The method of claim 1 , wherein before the mutation the tropoelastin has the amino acid sequence of SEQ ID NO: 4 or 5.
3. The method of claim 2 , wherein the amino acid sequence corresponding to SEQ ID NO: 106 (RAAAG) is the amino acid sequence at position 515 to position 519 of SEQ ID NO: 4 or 5.
4. The method according to claim 1 wherein one amino acid residue in the amino acid sequence corresponding to SEQ ID NO: 106 (RAAAG) is mutated.
5. The method according to claim 1 , wherein the arginine residue of the amino acid sequence corresponding to SEQ ID NO: 106 (RAAAG) is mutated.
6. The method of claim 1 , wherein the arginine residue of the amino acid sequence corresponding to SEQ ID NO: 106 (RAAAG) is replaced with an alanine residue.
7. The method of claim 1 , wherein the arginine residue of the amino acid sequence corresponding to SEQ ID NO: 106 (RAAAG) is replaced with a leucine residue.
8. The method of claim 1 , further comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 8 of SEQ ID NO: 4 or 5, to thereby further reduce the susceptibility of the tropoelastin to cleavage by thrombin.
9. The method of claim 1 , wherein before the mutation the tropoelastin has the amino acid sequence of SEQ ID NO: 4, and further comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 10 of SEQ ID NO: 4, to thereby further reduce the susceptibility of the tropoelastin to cleavage by kallikrein.
10. The method of claim 1 , further comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 14 of SEQ ID NO: 4 or 5, to thereby further reduce the susceptibility of the tropoelastin to cleavage by serum.
11. The method of claim 1 , wherein before the mutation the tropoelastin has the amino acid sequence of SEQ ID NO: 4, and further comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 15 or 16 of SEQ ID NO: 4, to thereby further reduce the susceptibility of the tropoelastin to cleavage by serum.
12. The method of claim 1 , further comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 11 or 12 of SEQ ID NO: 4 or 5, to thereby reduce the susceptibility of the tropoelastin to cleavage by plasmin.
13. The method of claim 1 , wherein before the mutation the tropoelastin has the amino acid sequence of SEQ ID NO: 4, and further comprising mutating one or more of the amino acid residues of the amino acid sequence corresponding to SEQ ID NO: 13 of SEQ ID NO: 4, to thereby reduce the susceptibility of the tropoelastin to cleavage by gelatinase B.
14. An isolated tropoelastin molecule produced by the method of claim 1 .
15. A method of reducing the susceptibility of tropoelastin to thrombin cleavage comprising replacing the alanine at any one of residues 516, 517 or 518 of SEQ ID NO:4 with another amino acid.
16. A method according to claim 15 , wherein the alanine corresponding to residue 516 of SEQ ID NO:4 is replaced with another amino acid.
17. A method of reducing the susceptibility of tropoelastin to cleavage by thrombin, kallikrein or serum, wherein the arginine residue corresponding to 515 of SEQ ID NO:4 is replaced with alanine.
18. A method of reducing the susceptibility of tropoelastin to proteolysis by thrombin, kallikrein or serum, consisting of mutating one or more of the amino acid residues corresponding to position 515 to 521 of SEQ ID NO: 4 in the tropoelastin, so that susceptibility of the tropoelastin to cleavage by thrombin, kallikrein or serum is reduced.
19. The method of claim 18 , wherein the amino acid residue at position 515 is arginine and is mutated.
20. The method of claim 18 , wherein the amino acid residue at position 515 is arginine and is replaced with alanine or leucine.
21. A method of reducing the susceptibility of tropoelastin to proteolysis by thrombin, kallikrein or serum protease, consisting of mutating arginine of the amino acid sequence corresponding to position 515 to 521 of SEQ ID NO: 4, so that susceptibility of the tropoelastin to cleavage by thrombin, kallikrein or serum is reduced.
22. The method of claim 21 , wherein the R in the amino acid sequence is replaced with A or L.
23. The method according to claim 21 wherein the tropoelastin is human tropoelastin.